{
    "clinical_study": {
        "@rank": "112831", 
        "brief_summary": {
            "textblock": "To determine drug efficacy and safety in HIV-infected patients treated with zidovudine ( AZT\n      ) versus stavudine ( d4T ) versus both drugs. Also, to compare short- and long-term changes\n      in magnitude of HIV RNA over time.\n\n      Asymptomatic patients with CD4 counts over 300 cells/mm3 are more likely to tolerate any of\n      the nucleoside analogs. d4T, with a favorable toxicity profile and demonstrated anti-HIV\n      activity in previous studies, provides an additional therapeutic option."
        }, 
        "brief_title": "The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs", 
        "completion_date": {
            "#text": "November 1997", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Asymptomatic patients with CD4 counts over 300 cells/mm3 are more likely to tolerate any of\n      the nucleoside analogs. d4T, with a favorable toxicity profile and demonstrated anti-HIV\n      activity in previous studies, provides an additional therapeutic option.\n\n      Patients are randomized to receive d4T alone, AZT alone, or both in combination for at least\n      12 weeks. After week 12, 3TC is added to the combination arm. Treatment continues for up to\n      48 weeks (was a total of 48 weeks, amended 3/26/96)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n          -  TMP / SMX, aerosolized pentamidine, or dapsone for PCP prophylaxis.\n\n        Allowed:\n\n          -  Atovaquone.\n\n          -  IV pentamidine.\n\n          -  TMP / SMX.\n\n          -  Trimetrexate.\n\n          -  Trimethoprim-dapsone.\n\n          -  Clindamycin-primaquine.\n\n          -  Topical antifungals.\n\n          -  Clotrimazole.\n\n          -  Ketoconazole.\n\n          -  Fluconazole.\n\n          -  Amphotericin B.\n\n          -  Itraconazole.\n\n          -  Rifabutin.\n\n          -  Isoniazid.\n\n          -  Pyrazinamide.\n\n          -  Clofazimine.\n\n          -  Clarithromycin.\n\n          -  Azithromycin.\n\n          -  Ethambutol.\n\n          -  Amikacin.\n\n          -  Ciprofloxacin.\n\n          -  Ofloxacin.\n\n          -  Pyrimethamine.\n\n          -  Sulfadiazine.\n\n          -  Clindamycin.\n\n          -  Filgrastim ( G-CSF ).\n\n          -  Up to 1000 mg/day acyclovir.\n\n          -  Erythropoietin.\n\n          -  Antibiotics.\n\n          -  Antipyretics.\n\n          -  Analgesics.\n\n          -  Antiemetics.\n\n          -  Rifampin.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Local radiation therapy.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  CD4 count 300 - 600 cells/mm3.\n\n          -  NO history of AIDS.\n\n          -  NO active opportunistic infection.\n\n          -  NO prior nucleoside therapy.\n\n          -  Life expectancy at least 2 years.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Serious underlying medical condition other than HIV such that life expectancy is less\n             than 2 years.\n\n          -  Malignancy requiring systemic cytotoxic chemotherapy.\n\n          -  Active grade 2 or worse peripheral neuropathy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretrovirals other than study drugs.\n\n          -  Systemic cytotoxic chemotherapy.\n\n          -  Foscarnet.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Chronic diarrhea defined as three or more stools per day for 15 days, within 30 days\n             prior to study entry.\n\n          -  Unexplained temperature >= 38.5 C for any 7 days within 30 days prior to study entry.\n\n          -  Active participation in other experimental therapy within 30 days prior to study\n             entry.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior nucleoside antiretrovirals of 1 week or longer duration.\n\n          -  Any antiretroviral within 90 days prior to study entry.\n\n          -  Non-nucleoside reverse transcriptase inhibitors and protease inhibitors within 30\n             days prior to study entry.\n\n          -  Biologic response modifiers such as IL-2 and interferon within 30 days prior to study\n             entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": "105", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001067", 
            "org_study_id": "ACTG 298", 
            "secondary_id": "11274"
        }, 
        "intervention": [
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Stavudine", 
                "Lamivudine", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "AIDS-Related Complex", 
            "Zidovudine", 
            "Stavudine", 
            "Lamivudine"
        ], 
        "lastchanged_date": "May 1, 2012", 
        "link": [
            {
                "description": "Click here for more information about Zidovudine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
            }, 
            {
                "description": "Click here for more information about Stavudine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=43"
            }, 
            {
                "description": "Click here for more information about Lamivudine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=126"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Alabama Therapeutics CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "Ucsd, Avrc Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20059"
                    }, 
                    "name": "Howard University Hosp., Div. of Infectious Diseases, ACTU"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "The Ponce de Leon Ctr. CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Adult AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63112"
                    }, 
                    "name": "St. Louis ConnectCare, Infectious Diseases Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington U CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NYU Med. Ctr., Dept. of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10003"
                    }, 
                    "name": "Beth Israel Med. Ctr. (Mt. Sinai)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Unc Aids Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "The Ohio State Univ. AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico"
                    }, 
                    "name": "Puerto Rico-AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Randomized Study of the Virologic and Immunologic Effects of Zidovudine Plus Lamivudine (3TC) Versus d4T Versus Zidovudine Plus d4T in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and No Previous Nucleoside Experience", 
        "overall_official": [
            {
                "last_name": "Havlir D", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Pollard R", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Richman D", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Friedland G", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "11365218", 
                "citation": "Cadman J. 2, 4, 6, 8, who's afraid to phosphorylate? GMHC Treat Issues. 1998 Feb;12(2):6-8. No abstract available."
            }, 
            {
                "citation": "Havlir DV, Friedland G, Pollard R, Tierney C, Smeaton L, Fox L, Richman DD. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleosides: report of two randomized trials (ACTG 290 and 298). Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:79 (abstract no 2)"
            }, 
            {
                "PMID": "12167276", 
                "citation": "Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):699-704."
            }
        ], 
        "removed_countries": {
            "country": "Puerto Rico"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001067"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Alabama Therapeutics CRS": "33.521 -86.802", 
        "Beth Israel Med. Ctr. (Mt. Sinai)": "40.714 -74.006", 
        "Howard University Hosp., Div. of Infectious Diseases, ACTU": "38.895 -77.036", 
        "Johns Hopkins Adult AIDS CRS": "39.29 -76.612", 
        "NYU Med. Ctr., Dept. of Medicine": "40.714 -74.006", 
        "Puerto Rico-AIDS CRS": "18.466 -66.106", 
        "St. Louis ConnectCare, Infectious Diseases Clinic": "38.627 -90.199", 
        "Stanford CRS": "37.442 -122.143", 
        "The Ohio State Univ. AIDS CRS": "39.961 -82.999", 
        "The Ponce de Leon Ctr. CRS": "33.749 -84.388", 
        "Ucsd, Avrc Crs": "32.715 -117.157", 
        "Unc Aids Crs": "35.913 -79.056", 
        "Washington U CRS": "38.627 -90.199"
    }
}